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Foreword 
 
This thesis constitutes the master thesis for the degree of Master of Philosophy 
(M. Phil.) in “Health economics, policy and management” at the University of Oslo. It was 
undertaken at the Norwegian Institute of Public Health during the period November 
2014-May 2015, as part of a project aimed at estimating the costs of antibiotics 
resistance in Norway. Resistance to antibiotics has become a serious worldwide 
problem as the number of pathogens that develop resistance to drugs is continuously 
increasing, and the development and production of new drugs is not keeping up with 
this increase.  Methicillin-resistant Staphylococcus aureus (MRSA) is the most common 
resistant bacterium in European countries. Norway is a low-prevalence country. A 
report based on 1,473 Staphylococcus aureus isolates from Norway indicates that less 
than 1% of these isolates are resistant to methicillin (MRSA) (European Centre for 
Disease Prevention and Control, 2013), but the arduous work to keep this under control 
is continuous and requires much effort from health authorities and personnel. The costs 
of these infections have been estimated through similar cost analyses in other European 
countries, i.e. the Swiss study conducted by Macedo-Viñas et al. (2013) in which they 
estimated the mean additional costs of MRSA infections based on excess length of stay to 
be €7,623, and the German study by Hübner et al. (2014) in which they estimate the 
mean additional costs of MRSA infections to be €8,625.  
The data from the Norwegian Surveillance System for Communicable Diseases 
and the Norwegian Patient Registry used in this cost analysis were provided by the 
Norwegian Institute of Public Health. The first data set we began to work with had a row 
of data for each patient based on every ward where they received care for one episode of 
inpatient care. This data set included the Diagnosis Related Group (DRG) code for each 
ward, rather than the hospital DRG code (refer to Figure 8). The hospital DRG code is the 
basis for reimbursement per episode of care. This created some difficulties in analysis, 
as we tried to capture our variables of interest for one episode of inpatient care. We 
requested a new data set from the Norwegian Patient Registry, which was received on 
April 1, 2015, that captured, in one row, the patient’s activity based on one episode of 
inpatient care. This was the data set used for our final analysis.  The Norwegian Institute 
of Public Health had also received ethical approval from the Regional Committees for 
Medical and Health Research Ethics (REC) for this project. We are very grateful for the 
opportunity provided by the Norwegian Institute of Public Health and for the assistance 
we received from Petter Elstrøm, Birgitte F. DeBlasio, Oliver Kacelnik, and Jørgen V. 
Bjørnholt. Our academic supervisor was Ivar Sønbø Kristiansen. 
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Abstract 
Background: Patients with Methicillin-resistant Staphylococcus aureus (MRSA) are 
thought to produce additional costs for hospitals, mainly driven by their length of stay 
and the costs associated with keeping the patients isolated.  
Objective: The aim of our study was to assess the costs of MRSA diagnosed patients 
based on their length of stay, number of episodes of care, and DRG reimbursement, as 
well as to map out the characteristics of this patient group.   
Methods: Our analyses were based on data from the year 2012 for the South-Eastern 
Norway Regional Health Authority as reported and registered in the Norwegian 
Surveillance System for Communicable Diseases and the Norwegian Patient Registry. We 
estimated excess length of stay by: (i) matching MRSA diagnosed inpatients with non-
MRSA inpatients according to DRG code; (ii) matching MRSA diagnosed inpatients with 
non-MRSA inpatients based on hospital ward. We estimated the economic burden by: (i) 
matching MRSA diagnosed inpatients with non-MRSA inpatients based on primary 
diagnosis and then found the mean DRG reimbursement per group; (ii) matching MRSA 
diagnosed inpatients with non-MRSA inpatients based on hospital ward and compared 
the mean DRG reimbursement; (iii) matching MRSA diagnosed outpatients and day 
patients with non-MRSA patients based on ward and compared the mean DRG 
reimbursement. We estimated episodes of care by: (i) matching all MRSA diagnosed 
patients with non-MRSA patients based on hospital ward; (ii) matching MRSA diagnosed 
outpatients and day patients to non-MRSA patients based on ward to compare the 
number of subsequent episodes of hospital care per group.  
Results: The mean length of stay for MRSA inpatients (n=174) was 8.5 and 8.2 days 
compared with controls, who had a mean length of stay of 5.4 and 4.6 days when 
matched on DRG code and ward, respectively. The DRG reimbursement for MRSA 
inpatients was NOK71,206 and NOK74,644 compared with NOK56,653 and NOK49,511 
for controls matched based on primary diagnosis and ward, respectively. MRSA 
inpatients had nearly double (1.5) the number of subsequent episodes per patient 
compared with controls (0.8) matched on ward. All MRSA patients (n=315), outpatients 
(n=241), and day patients (n=20), had fewer subsequent episodes of care compared 
with their controls. 
Conclusion: This analysis indicates the economic impact of patients with MRSA 
diagnoses, having 26%-50% higher costs than others. Further detailed cost-
effectiveness analysis is advised so that policy makers can make informed decisions 
regarding infection control measures. 
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1. Introduction (both authors) 
Staphylococcus aureus is classified as a gram-positive aerobic organism that is 
considered to be one the most frequently diagnosed bacterium in this category 
(Levinson, 2008). The bacterium is associated with several types of infections, most 
commonly skin and soft tissue infections, although it may also cause more severe 
infections of the bone and bloodstream (World Health Organization, 2014). Certain 
strains of Staphylococcus aureus can mediate toxin production that may lead to toxic 
shock syndrome, scalded skin syndrome, and food poisoning (Levinson, 2008), and it is 
also a leading cause of bacterial infections responsible for a number of diseases and life-
threatening conditions, such as septicemia, pneumonia and endocarditis (Christenson, 
Ardung and Sylvan, 2011). 
 
1.2 Methicillin-resistant Staphylococcus aureus (MRSA) (both authors) 
Methicillin, the first anti-resistance antibiotic, was introduced in 1959 as a 
response to the bacterium’s resistance to penicillin. Within three years of the 
introduction of methicillin, Methicillin-resistant Staphylococcus aureus (MRSA) (Figure 
1) appeared (Davies and Davies, 2010). MRSA has since become a frequent cause of 
nosocomial infections and is associated with increased mortality and morbidity (Hübner 
et al., 2014). Patients who undergo organ transplantations, hemodialysis, as well as 
some cancer treatments are particularly susceptible to multidrug-resistant bacterial 
infections when receiving treatment for underlying diseases (European Centre for 
Disease Prevention and Control, 2009).  
A meta-analysis of 30 studies by Cosgrove et al., (2003) found that the average 
mortality rate of septicemia was ~36% for MRSA compared to ~24% for methicillin-
susceptible Staphylococcus aureus (MSSA). The Epic II study, an international study 
including data from 1,265 participating Intensive Care Units (ICU) from 75 countries, 
assessed the increased risk of death of MRSA infected patients in ICU compared to 
patients who were infected with MSSA while in ICU. Their results showed that MRSA 
was associated with an increased risk of hospital death of almost 50% compared to 
MSSA (Hanberger et al., 2011).  
In the joint technical report, “The bacterial challenge; time to react”, by the 
European Centre for Disease Prevention and Control (ECDC) and the European 
Medicines Agency (EMEA), it is shown that MRSA is the most common multidrug-
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resistant bacterium, among those under surveillance in the European Union (EU) (ECDC, 
2009). The World Health Organization (WHO) estimates in its report from 2014, “The 
evolving threat of antimicrobial resistance”, that people with MRSA are 64% more likely 
to die than people with a non-resistant form of the infection. They also increase the cost 
of health care through lengthier hospital stays, estimated at 2,5 million extra hospital 
days, and extra in-hospital costs of more than €900 million in 2007 (ECDC, 2009).  
At least 2 million people acquire serious infections with resistant bacteria each 
year in the United States, and it is estimated that at least 23,000 die as a direct 
consequence of these antibiotic-resistant bacteria (U.S. Department of Health and 
Human Services, 2013).  This same report estimates that 80,461 invasive MRSA 
infections and 11,285 related deaths occurred in the United States in 2011. The 
prevalence of Staphylococcus aureus isolates that are resistant to methicillin (MRSA) is 
high in the rest of the world, from an average between 22%-25% in the EU (ECDC, 2009) 
to an average of 80%-90% in some health care settings in the Americas and Africa 
(WHO, 2014).   
 
 
 
Figure 1: Staphylococcusaureus 
(Motility research, 2015) 
Staphylococcusaureus occur in clusters that resemble grapes (Staphylo) 
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1.2.1 Epidemiology (A.E.S.A.) 
 
Staphylococcus aureus is a normal inhabitant in the human body, found 
permanently in the nose of 20%-30% of adults and sometimes on the skin  (Levinson, 
2008). It spreads from person to person by direct contact and through contaminated 
objects, rarely, but also possibly, through inhalation of contaminated droplets (Levinson, 
2008). 
Methicillin-resistant strains of Staphylococcus aureus (MRSA) are frequently 
categorized as either hospital- or healthcare-associated (HA-MRSA) and community-
associated (CA-MRSA) infections (Enright, 2006). HA and CA-MRSA are genetically 
different, and therefore, CA-MRSA may be susceptible to other antibiotics than HA-
MRSA, although the same drugs used to treat HA-MRSA may be effective against CA-
MRSA (Levinson, 2008). There is an important distinction between MRSA colonization 
and infection. Patients who are deemed colonized have the bacteria present in their 
body, whereas, patients with active infections present with clinical symptoms (Levinson, 
2008). The origins of both HA and CA-MRSA are rooted in improper use of this type of 
medication (Figure 2).  
 
 
Figure 2: Examples of how antibiotic resistance spreads 
 (U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 
2013, p. 14) 
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1.2.2 The nature of antibiotics and bacterial resistance mechanisms (A.E.S.A.) 
 
Before we explore how resistance mechanisms work, we must understand how 
antibiotics and antimicrobials in general act when administered to a patient. These 
drugs have the ability to act against selected bacterial or microbial functions without 
disadvantaging the host. Antimicrobial agents can be roughly classified into two main 
categories: bacteriostatic and bactericidal (Sosa et al., 2009). Bacteriostatic antibiotics 
and antimicrobial agents inhibit the growth and multiplication of the bacteria so the 
patient’s immune system gets time to fight them and get rid of them, while bactericidal 
antimicrobial agents kill the bacteria regardless of the patient’s immunity (Sosa et al., 
2009). 
Some bacteria are naturally resistant to certain antibiotics because they do not 
have target sites for the medication or because they naturally have low permeability to 
the agents in the medication due to differences in the chemical composition of the 
medication and the microbial membrane (Sosa et al., 2009). According to the Norwegian 
Institute of Public Health, bacteria may develop resistance to antibiotics in two main 
ways: 
 Mutations in the genetic material (DNA) after exposure to antibiotics in the 
environment 
 Transfer of resistance genes from other bacteria 
Resistance mechanisms are developed depending on the specific pathways that the drug 
is intended to act on (Figure 3).   
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Figure 3: Sites of action and potential mechanisms of bacterial resistance to antimicrobial 
agents 
 
(Canadian Medical Association (CMAJ), 2015) 
 
 
Some important events in the development of antibiotic resistance include the 
discovery of Penicillin-resistant Staphylococcus aureus in 1940, the introduction of 
methicillin in 1960 and the development of resistance to the same by Staphylococcus 
aureus in 1962 (Figure 4).  Bacteria have adapted and developed resistance to any drug 
intended to work against them. The main challenge with this is that, currently, there are 
no new drugs being developed for these purposes due to lack of return on investment 
for large pharmaceutical companies (Piddock, 2011). 
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Figure 4: Timeline showing key events in antibiotic resistance from 1940 to 2011 
(U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 
2013,p. 28) 
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1.3 Norway 
1.3.1 Health care organization (C.J) 
 The Norwegian health care system is structured on three levels: national, 
regional, and local. The Ministry of Health and Care Services is the national branch that 
provides oversight, allocates the health care budget, and writes legislation for the 
provision of health care, among other responsibilities (Johnsen, 2006). Johnsen states 
that, “the Ministry of Health and Care Services is responsible for administering the 
following services: primary health care, specialized health care, public health, mental 
health, medical rehabilitation, dental services, pharmacies and pharmaceuticals, 
emergency planning and coordination, policies on molecular biology and biotechnology 
and nutrition and food safety” (Johnsen, 2006, p. 16).  
The provision of specialist health care is the primary responsibility of the 
regional health authorities. According to the South-Eastern Norway Regional Health 
Authority’s website (2015), specialist care includes hospitals, psychiatric and substance 
abuse treatment institutions, ambulance service, emergency service response, patient 
transportation, rehabilitation institutions, hospital pharmacies, and laboratories. The 
regional level of the health care system is divided into four geographic regional health 
authorities: North, Central, West, and South-East. Below in Figure 5 is a depiction of 
these four regions.  
 
Figure 5: Map of Norway’s Regional Health Authorities 
  (Norwegian Government, 2015) 
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The Regional Health Authorities are responsible for providing specialist care 
services through their hospital trusts (also known as hospital enterprises) and 
individual hospitals within their region (Figure 6).  
 
 
 
Figure 6: The structural organization of specialized care in Norway 
(Adapted from Magnussen, Hagen, and Kaarboe, 2007) 
 
 
The South-Eastern Norway Regional Health Authority is comprised of seven 
hospital regions (Figure 7) with ten hospital trusts, as reported by their website (Helse 
Sør-Øst, 2015). According to the South-Eastern Norway Regional Health Authority 
annual report from 2012, the area included 2.8 million residents, which accounted for 
56% of the Norwegian population in 2012. The total revenue for the year was NOK65 
billion, of which, NOK15.4 billion was activity-based financing (Helse Sør-Øst, 2012).  
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Figure 7: Map of the South-Eastern Norway Regional Health Authority with its seven hospital 
regions 
(Helse Sør-Øst,2012, p. 3) 
 
With regard to primary health care, Johnsen (2006, p. 19) states that 
municipalities are responsible for funding and provision. This includes curative and 
preventative treatment like: 
 “Promotion of health and prevention of illness and injuries, including 
organization and running school health services, health centres, child health 
care provided by health visitors, midwives and physicians.” 
 “Diagnosis, treatment and rehabilitation.” 
 “Nursing care within and outside institutions.” 
 
1.3.2 Health care financing (A.E.S.A.) 
 Activity-based financing rooted in the Diagnosis Related Groups (DRG) system for 
somatic inpatient activity was first implemented in Norway in 1997 (Johnsen, 2006). 
The financing of the regional health authorities is from two sources: block grants and 
activity-based financing. The regional health authorities are responsible for the 
 18 
distribution of funds to hospitals and other service providers (Norwegian Government, 
2014). For the year 2012, the block grant made up 60% and activity-based financing 
made up 40%, for financing somatic hospitals in Norway. The basic funding of the 
regional health authorities is a yearly grant independent of the level of activity; instead, 
it is based on the number of inhabitants in the region and their age composition 
(Norwegian Government, 2014).  
The DRG system is a method for classifying patients. Hospital stays or outpatient 
consultations in somatic institutions are classified into groups that are clinically and 
economically similar (Norwegian Directorate of Health, Activity-Based Financing, 2012). 
DRG codes classify medical cases according to primary and secondary diagnoses, patient 
age, gender and comorbidities, the procedures performed and complications, if any 
(Cylus and Irwin, 2010). Primary diagnosis is incorporated into the DRG that has been 
selected as the principal DRG for hospital reimbursement purposes (Figure 8). The 
selection of the principal DRG is done by a computer software and algorithm, meaning 
that hospitals and doctors cannot select which DRG code they would prefer to use for 
reimbursement purposes.  
 
 
Figure 8: The aggregation of ward DRG codes to hospital reimbursed DRG 
(Adapted from the Norwegian Directorate of Health, 2012) 
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Outpatient consultations generate lower DRG reimbursements than day patient 
consultations because outpatients are subject to a co-payment. This co-payment is 
deducted from the total cost when setting the DRG for outpatients, thus, resulting in 
lower DRG weights when compared to day patient DRGs (Norwegian Directorate of 
Health, 2012). 
Over the years, government health care expenditure in developed countries has 
increased faster than their Gross Domestic Product (GDP) (National Bureau of Economic 
Research, 2005). These authors claim that this development must be seen in conjunction 
with country-specific age-health expenditure profiles, as demographics and the total 
number of beneficiaries have increased (Figure 9 and 10). The population size has 
increased in most countries, women’s fertility has dropped and the share of the 
population that is elderly has increased in developed countries (Bongaarts, 2009). 
Health expenditure per capita tends to be associated with income per capita, which may 
explain why Switzerland and Norway had the highest figures in 2010, with spending 
above €4,000 per person, followed by the Netherlands (€3,890), Luxembourg (€3,607), 
and Denmark (€3,439) (Figure 11).  
 
 
 
Figure 9:Total health expenditure as a share of GDP, 2010 (or nearest year) 
(Organization of Economic Cooperation and Development, 2012, p. 123) 
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Figure 10: Annual average growth in health expenditure and GDP per capita, in real terms, 
2000-2010 (or nearest year) 
(Organization of Economic Cooperation and Development, 2012, p. 121) 
 
 
 
 
 
Figure 11:Health expenditure per capita, 2010 (or nearest year) 
(Organization of Economic Cooperation and Development, 2012, p. 121) 
 
1.3.3 Antibiotic resistance and MRSA in Norway (A.E.S.A.) 
A joint report from 2012 by NORM, which is the Norwegian surveillance program 
for antimicrobial resistance in human pathogens, and NORM-VET, which is a monitoring 
program for antimicrobial resistance in animal pathogens and the food production 
sectors, says that in 2012, the consumption of penicillin for humans, measured in 
Defined Daily Doses, accounted for 41% of the total antibiotic use (NORM/NORM-VET, 
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2012). Over the years, although the total sale of antibiotics in Norway has remained 
stable, the sale of narrow-spectrum penicillin has decreased while broad-spectrum 
penicillin has increased (Norwegian Ministry of Health and Care Services, 2008).  
The number of reported cases of MRSA infections and colonization in Norway 
between 2010 and 2012 deserves attention from the health authorities. According to the 
Norwegian Surveillance System for Communicable Diseases, the number of MRSA 
infections and colonizations reported in 2012 was 575 and 633 respectively, compared 
to year 2010 when 429 infections and 478 colonizations were reported. This is a 34% 
increase in the number of infections and 32% increase in the number of colonizations 
from 2010 to 2012.  Although, these figures are still very modest compared to other non-
Scandinavian countries, it is a negative development for Norway. Therefore, we must not 
only prevent and control the spread of MRSA, but we must also estimate the economic 
burden posed to the Norwegian health care system. 
 
 
Figure 12:Infection and colonization with Methicillin-resistant S. aureus (MRSA) in Norway 
2006-2013 
(Norwegian Surveillance System for Communicable Diseases, 2015) 
 
1.3.4 National guidelines and containment protocol (both authors) 
In 2009, the Norwegian Institute of Public Health and the Norwegian Health 
Directorate published a manual that included specific measures to be taken to prevent 
an endemic presence of MRSA in the bacterial flora of Norwegian health institutions 
(Norwegian Institute of Public Health, 2009). These guidelines are well implemented at 
all levels of the health care system. There are important principles, anchored in 
Norwegian law, governing the actions taken to prevent and control the spread of MRSA 
in Norwegian health facilities: 
0
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 Suspected or confirmed MRSA colonization or infection must not delay necessary 
examination, treatment or care 
 Measures against MRSA can only be taken with the patient’s consent 
 Measures against MRSA should not put limitations to the patient’s life beyond the 
prevention and control measures taken when in contact with the health care 
system 
 
Basic infection control routines are based on the principle that all bodily fluids, such as 
blood, secretions and excretions (except sweat), torn skin and mucous membranes, may 
contain infectious agents. 
 
Hospitals: In this setting, there is an active “search and destroy” MRSA practice, 
meaning that they examine persons who may have an increased risk of having MRSA at 
admission or employment, as well as tracking all contacts had by a newly detected case 
of MRSA in the hospital. The spread of infection is controlled by isolation of MRSA 
positive patients, work restrictions for care personnel who test positive for MRSA, and 
sanitation of colonization.Patients are screened before hospital admission if they meet 
the following criteria: 
 Previously tested positive, without subsequently having three negative tests 
 Have clinical symptoms, chronic skin disorders or have had medical equipment 
put through their skin or mucous membrane in the last 12 months in a foreign 
health care facility 
 
Or in the last 12 months: 
 Been diagnosed MRSA (even with a negative test outcome) 
 Lived with someone who is MRSA positive 
 Been in close contact without protective equipment 
 
Or in the last 12 months have been abroad and: 
 Been admitted to a health care facility 
 Received extensive treatment or an exam in a health care facility 
 Worked as a health care worker  
 Stayed in an orphanage or refugee camp 
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In addition, a MRSA test is taken of all who have clinical symptoms on their skin 
or bruise infection, chronic skin conditions or permanent medical equipment inserted 
through their skin or mucous membranes, and who have been outside of Scandinavia for 
more than 6 consecutive weeks during the last 12 months. An unexpected detection of 
MRSA may lead to examination of all health care personnel and all patients in a specific 
ward.  
Patients who are suspected of having MRSA are preemptively isolated until 
laboratory results indicate otherwise. Of those who test positive as either colonized or 
infected during their screening, isolation protocol is applied for the remainder of their 
hospital stay. This includes isolating the patient to a single room and using infection 
control measures, such as, wearing surgical masks, gloves, and gowns each time health 
personnel enter the room. Isolation protocol may also be applied to patients who are 
particularly vulnerable of contracting an infection. After a patient is either discharged or 
transferred, the cleaning personnel follow an extensive disinfection protocol.  
Persons with MRSA may be offered sanitation of colonization. Control tests are 
carried out one, two, and three weeks after sanitation.  New control tests are 
recommended three, six, and twelve months after sanitation of MRSA.  
 
2. Literature review (A.E.S.A.) 
Several studies in Europe and the US have attempted to estimate the additional 
resource use (costs) associated with MRSA, and excess length of stay has been found to 
be a leading cause of increased costs for hospitals (Macedo-Viñas et al., 2013). Other 
studies have shown that there is an expected additional length of stay between 3-25 
days for patients with MRSA as compared to patients with MSSA (Macedo-Viñas et al., 
2013).  
 
2.1 Previous studies (A.E.S.A.) 
Although we believe increased resistance poses a huge burden on economies, 
there are currently few studies that establish the economic burden of MRSA diagnoses in 
Norwegian hospitals. Tri Chinh Nguyen from the University of Tromsø (2009) conducted 
a cost-effectiveness analysis of antibiotics used to treat MRSA infections, and his 
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objective was to establish which intervention was the most cost-effective, not to 
establish the economic burden of the disease. 
Brith Christenson et al. carried out a study in 2011 on MRSA infections in Uppsala 
county in Sweden. In this study they identified MRSA clones originating in Sweden and 
outside of Sweden. The cost per identified case of HA-MRSA was SEK216,700, while the 
cost per case of CA-MRSA was SEK38,000, possibly indicating that the patients who 
acquire MRSA while in hospital are already very sick, and that the cost of isolation plays 
an essential part when estimating the economic burden of MRSA infections. 
A Swiss study from 2013 by Macedo-Viñas et al., estimated the economic burden 
of MRSA infections at Geneva University Hospital by multiplying excess length of stay for 
MRSA infected patients with bed-day costs.  The authors compared average length of 
stay of MRSA negative with MRSA positive patients, using multistate modeling, which 
means that they compared MRSA positive with MRSA negative, and then compared 
MRSA infections with MRSA colonizations. Their findings showed that MRSA infections 
produced an average excess length of stay of 11.5 days and additional cost of CHF800 
per case per day (€663 in 2012), meaning approximately €7,625. 
Most recently, in October 2014, Hübner et al. published a paper on MRSA 
attributed costs of hospitalized patients in Germany. Their aim was to assess the 
additional cost of MRSA management measures, as well as identify the main cost drivers 
from the hospital’s perspective. This study was based on a single hospital and 182 
patients. They arrived at an MRSA attributed cost of €8,673 per case, including hygienic 
measures and laboratory costs. 
With respect to the prevalence of MRSA in Norway, a time series analysis by John 
F. Moxnes et al. (2013) has studied the trends of MRSA infections in Norway and 
concluded that the proportion of MRSA in relation to the total number of Staphylococcus 
aureus positive tests is increasing in Norway. This is also supported by the number of 
registered cases of MRSA in theNorwegian Surveillance System for Communicable 
Diseases, which may be a consequence of increased screening following the 
implementation of the national guidelines for handling MRSA. 
 
2.2 Current situation (A.E.S.A.) 
To our best knowledge, there are currently no studies estimating the economic 
impact of MRSA positive patients in Norwegian hospitals. Some studies have looked at 
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the cost-effectiveness of drugs used to treat MRSA infections (Nguyen, 2009) and the 
development in the number of MRSA cases in Norway (Moxnes et al., 2013). Our aim is 
to contribute to this field with our findings on costs related to extended hospital stays 
for patients through the analysis of data from the South-Eastern Norway Regional 
Health Authority from the year 2012. 
 
3. Theory 
3.1 Costs (C.J.) 
When considering economic evaluation in health care, we must first define how 
we identify costs. The consumption of health care resources by one patient at some time 
and place means that at the same time and place, those health care resources are not 
available for another purpose. In other words, the consumption of health care resources 
has limits. The cost of care can thus be understood as the consumption of health care 
resources. The value of this resource, or the cost we assign to it, is the opportunity cost 
of the resource (Hunink, 2001). Put in other terms, it is the benefit that is forgone by not 
investing in the alternative health care treatment or program that those same resources 
could have been allocated to (Olsen, 2009).  
The perspective of an economic evaluation will determine how we define 
opportunity cost. Various perspectives that may be considered include societal, hospital, 
governmental, and that of the insurer. The types of costs that may be accounted for will 
also depend on the perspective from which the analysis is done. From a hospital 
perspective, the costs of health care resources are most important, and within that 
category, the time of health care personnel is most significant (Hunink, 2001). Other 
non-health care resource costs that may be accounted for in an analysis performed from 
the societal perspective include transportation for patients, the patient’s time, 
caregiver’s time, and the productivity lost by the patient being unable to work, among 
other costs. Within each perspective there are two levels of costs to consider, gross-
costing and micro-costing. Gross-costing includes an existing set of prices, such as, the 
DRG reimbursement rate. Micro-costing accounts for inputs of service and retrieving 
data on price per unit, so that a cost estimate can be calculated (Hunink, 2001). For 
example, the cost per unit of sterile gowns worn by hospital staff when they enter rooms 
where this protocol applies may be multiplied by the number of units used to find the 
micro-cost of gowns.  
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After the perspective is defined and types of costs and level of costing are 
decided, understanding the difference in average versus marginal costs becomes 
imperative when considering decision making of health care resource distribution. To 
calculate the average or the marginal cost, a distinction that needs to be made is the 
difference between fixed costs and variables costs. In his book, The Principles in Health 
Economics and Policy, Jan Abel Olsen clarifies the difference between fixed and variable 
costs. The costs of a hospital building or machinery are considered fixed input factors 
and are termed fixed costs, since they are not dependent on a health care facility’s level 
of productivity. Inversely, the variable costs may change based on productivity. Such 
costs would include labor hours and medical supplies (Olsen, 2009). Olsen then explains 
the calculation of total cost (TC) as the fixed costs (FC), added to the variable costs (V); 
with the variable costs being multiplied by the quantity (X) used i.e. number of labor 
hours (Olsen, 2009, p. 196).  
 
The formula Olsen (2009) provides for calculating total cost is: 
TC=FC+V (X) 
To calculate the average costs (AC) Olsen (2009) provides the following: 
AC=TC/X 
The marginal costs (MC) “…are the additional costs following a one-unit change in 
production” (Olsen, 2009, p. 196). To calculate the marginal costs Olsen (2009) gives the 
formula: 
MC=V (X+1)-V (X) 
 
Using marginal costs is the general rule for economic evaluations that include 
priority setting regarding health care resource distribution (Hunink, 2001). Olsen 
(2009) illustrates the significance of this distinction by citing the Neuhauser and Lewicki 
study from 1975 of the costs of guaiac stool testing. To detect bowel cancer, six 
sequential tests were recommended by medical specialists. The study found that the 
average cost of the six tests was $2,451 per cancer detecting test. When considering that 
the incremental detection rate decreased heavily with each test, they found that the 
marginal cost for the sixth test detecting cancer was $47 million (Olsen, 2009). This 
example is quite extreme, but one can also understand practically that the first day in 
the hospital for a hip replacement surgery is going to be much more expensive than the 
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day of discharge. Thus, when informed decisions are to be made about health care 
resource allocation, marginal cost must be used rather than average costs. 
 
3.2 Economic Evaluation(C.J.) 
Economic evaluation has theoretical basis in welfare economic theory, which 
infers that decisions regarding health care expenditures should be regarded in the same 
way as non-health care related expenditures. What is of interest in decision making in 
welfare economic theory is whether or not a change in resource allocation represents a 
Pareto improvement in social welfare (Briggs et al., 2006). Pareto improvement is 
defined as, “a policy that makes one or more persons better off and makes no person any 
worse off” (Drummond et al., 2005, p. 217). 
According to Drummond et al. (2005, p.7), there are two questions of interest in 
economic evaluations. 
1. “Is this health procedure, service, or programme worth doing compared 
with other things we could do with these same resources?” 
2. “Are we satisfied that the health care resources (required to make the 
procedure, service, or programme available to those who could benefit from it) 
should be spent in this way rather than some other way?” 
 
There are two important features that characterize economic evaluation analysis. 
The first is that it incorporates both costs and consequences. The second is that 
economic evaluation is concerned with choices. These two features define economic 
evaluation as, “the comparative analysis of alternative courses of action in terms of both 
their costs and consequences” (Drummond et al.,2005, p. 9). The three primary forms of 
analyses in economic evaluation are cost-effectiveness analysis, cost-benefit analysis, 
and cost-utility analysis. The distinguishing feature of each is how they measure 
consequences or outcomes. Cost-effectiveness analysis compares costs in relation to a 
common outcome, such as life-years gained, which may be different in consequence 
between different programs. Cost-benefit analysis translates outcomes into monetary 
units and compares costs. Finally, cost-utility analysis measures outcomes in terms of 
utility, such as health-related quality of life (Drummond et al., 2005).  
Although we will not be performing decision analysis, our cost analysis of MRSA 
will be based in our disciplinary foundations of economic evaluation rooted in welfare 
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economic theory. It is from within framework that we will assess the cost burden of 
MRSA. As we are not performing decision analysis, our results are not recommended for 
priority setting. Rather, they may be considered as a reference for future economic 
evaluations. 
 
3.3 Principal-Agent Theory(C.J.) 
The Principal-Agent Theory can be used as a framework to define how the 
Norwegian health system works. Principal-Agent Theory provides a flexible framework 
for modeling variations in institutional arrangements and comparing their potential to 
generate the desirable behavior by the agents (Gailmard, 2012). Briefly accounted, the 
principal must produce an incentive scheme that leads the agent to choose the 
principal’s preferred action. This influence fails in relationships where there is 
information asymmetry, meaning that one party possesses information that the other 
party does not, such as the agent having more information than the principal. It also fails 
where there is moral hazard, which means that the agent would choose a series of 
actions normally considered inappropriate if the payment scheme puts all the risk on 
the principal (Miller, 2005).  
Within health care, the principal-agent relationship is between the patient as the 
principal, and the physician as the agent. Physicians in this relationship are always 
expected to apply their expertise and skills to the betterment of the principal’s health, 
and never to their disadvantage (Zweifel et al., 2009) In reality, physicians have more 
knowledge and power than patients when it concerns making informed decisions about 
medical care, hence, there is information asymmetry in the patient-physician 
relationship.  As a consequence, within health care systems, a third party is introduced 
to offset the conflict of interest between the patient-physician relationship. This third 
party is referred to as a complementary agent, and is usually represented by either an 
insurer or policy maker (Zweifel et al., 2009).  
In the Norwegian national insurance scheme, this is the policy maker’s role. The 
two main tasks of a complementary agent are to ensure quality and negotiate 
remuneration. This third party is meant to resolve the conflict of interest between the 
patient and the physician (Zweifel et al., 2009). The diagram below, borrowed from 
Zweifel et al., is a depiction of this relationship. 
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Figure 13: Principal-agent relationship in the Norwegian national insurance scheme 
 (Adapted from Zweifel, 2009, p. 380) 
 
When considering the economic burden of MRSA in hospitals in light of the 
principal-agent relationship, we can better understand the advantages of knowing the 
costs associated with MRSA. Policy makers hope to ensure that there is no disincentive 
for hospitals to act in the best interest of the patient. The cost burden of MRSA is 
important to define for not only the hospitals treating these cases, but also for the 
overall health care budget and society. 
 
3.4 DRG payment systems (A.E.S.A.) 
The prospective DRG based payment system was originally introduced in the 
United States in the late 1970s when policy makers were forced to radically reform 
Medicare in order to avoid insolvency for the program (Mayes, 2007). Until then, 
Medicare had reimbursed hospitals whatever they charged for treating Medicare 
patients. This situation changed with the introduction of the DRG, under which system 
Medicare paid hospitals a predetermined amount based on the patients diagnosis 
(Mayes, 2007). 
DRG based payment systems were eventually introduced in a number of 
countries. The main objectives of these systems were cost containment, to increase 
efficiency, or to improve transparency in hospital activities (Mathauer and 
Wittenbecher, 2013). 
Norwegian regional health authorities, which are in charge of administering 
funds to hospitals, receive a fixed share of 60% of their income from the government 
 30 
while 40% is activity-based financing through DRGs. There is currently no systematic 
method for accounting for the additional cost of MRSA. When a hospital receives a MRSA 
colonized or infected patient, it faces a dilemma when choosing to treat the patient in 
the hospital and incur the potentially high costs of a lengthy stay in isolation, or to send 
the person home. The latter alternative would allow the hospital to prevent potential 
spread of MRSA, save costs, and at the same time be able to offer hospital beds to other 
patients, increasing the hospital’s activity. 
The activity-based reimbursement to Norwegian hospitals was 40% of the total 
estimated costs in 2012 (Norwegian Directorate of Health, 2012). According to S.O. 
Petersen (2010), this offers a strong incentive for the hospitals to maximize the patient 
volume and hence the number of DRG points. Petersen also notes that the mean length 
of stay at Norwegian hospitals has been decreasing annually, from 5.67 days in 2002 to 
4.75 days in 2008. At the same time, the readmission rate has increased by roughly 15%. 
In theory, this decrease in the length of stay and increase in readmissions can be 
explained by the imbalance in the principal-agent relationship, as well as the 
complementary agent’s lack of knowledge to offset the balance. 
Perencevich et al. (2007), in their article titled, “Raising Standards While 
Watching the Bottom Line: Making a Business Case for Infection Control,” make a strong 
case for the need to ensure infection control measures are financially incentivized. In the 
United States, which is the context the authors are writing from, infection control 
programs are often seen as areas where there is potential for budget cuts. The authors 
encourage high quality cost-effectiveness evaluations when hospital administrators are 
making decisions regarding infection control. The foundation for a cost-effectiveness 
analysis is obtaining data on incidence rates and attributing costs to those incidences. 
We hope that our cost analysis will serve to encourage a proper cost-effectiveness 
analysis so that informed decision-making is possible. 
 
4. Objectives and Hypothesis (both authors) 
The overarching objective of this study was to estimate the costs associated with 
the patients diagnosed with MRSA who received specialized care, and to characterize 
this patient population using data from the South-Eastern Norway Regional Health 
Authority as reported and registered in Norwegian Surveillance System for 
Communicable Diseases and the Norwegian Patient Registry during the year 2012.  This 
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was done by finding the mean length of stay per hospital admission for MRSA diagnosed 
inpatients compared with non-MRSA inpatients. In addition to length of stay, the 
average reimbursement based on the DRG cost weight and the average number of 
subsequent episodes of care, were used as proxies for resource use.  
We hypothesized that MRSA inpatients have a longer length of stay on average 
than non-MRSA inpatients, and that they also have more episodes of care and are more 
costly based on their DRG reimbursement amount.  
Our aim was to address the following questions: 
 What are the characteristics of patients with MRSA in terms of age and gender? 
 How many subsequent episodes of hospital admission did MRSA patients have on 
average in 2012? 
 Do patients diagnosed with MRSA have lengthier stays in the hospital compared 
with non-MRSA patients? 
 What is the average DRG based reimbursement amount for MRSA patients at all 
levels of specialized care (inpatient, outpatient, day patient)?  
 Are there any particular characteristics that distinguish this sample population or 
could bias our findings? 
 
5. Methods 
5.1 Study design and data (both authors) 
This was a register-based case-control study using data for 2012. The data in our 
analyses stemmed from two sources: the Norwegian Patient Registry and the Norwegian 
Surveillance System for Communicable Diseases. The linkage of these data sets was the 
result of a pilot program run by the Norwegian Institute of Public Health from 2012, and 
was restricted to the South-Eastern Norway Regional Health Authority (Helse Sør-Øst). 
These data were intended to create a dynamic disease model displaying the spread of 
MRSA within hospitals. Thereafter, the Ministry of Health and Care Services requested a 
cost analysis to be done with these data. This project was meant to test methodological 
approaches for future cost analyses of MRSA at the Institute of Public Health.  
In order to estimate the costs associated with patients suffering from MRSA 
infection, it is important to distinguish between colonization and actual infections 
(clinical disease), because colonization of the MRSA bacterium may not need in-hospital 
care until another underlying condition weakens their immune system and sets the 
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proper conditions for the bacterium to cause harm. An infected person, on the other 
side, is usually already sick and may have gotten the infection in hospital. Given the 
challenges posed by an MRSA infection, this will probably result in a higher cost per case 
of MRSA infection than MRSA colonization. However, for the purpose of our analysis 
from a hospital perspective, colonization and infection have been treated equally as 
MRSA positive, as the guidelines for treating both colonized and infected patients are the 
same.   
 
5.2 Norwegian Surveillance System for Communicable Diseases 
(A.E.S.A.) 
TheNorwegian Surveillance System for Communicable Diseases (MSIS) is run by 
the National Institute of Public Health. Microbiological laboratories that analyze 
specimens from humans, as well as all doctors in the country, are required by law to 
notify cases of certain diseases to this central surveillance system (Norwegian 
Surveillance System for Communicable Diseases, 2015).  Therefore, information from 
MSIS is generated through compulsory reporting of all notifiable diseases detected in 
Norwegian inpatient and outpatient facilities. All patients reported with MRSA infection 
or colonization status (among other diseases) to the Norwegian Institute of Public 
Health, have been registered in the MSIS database since 1995 (Norwegian Institute of 
Public Health, 2010). Patients are diagnosed with MRSA through microbiological 
laboratory testing of samples taken from various sites of the body including the throat, 
nares, perineum, fresh scars/skin lesions/wounds/eczema, and insertion sites of 
catheters. There is no registration of clearance of MRSA. 
MSIS has existed nationwide since 1975, but in 2003 legislation granted more 
authority and responsibility to the surveillance system as a response to increasing 
challenges in infectious disease control (Norwegian Institute of Public Health, 2007).  
 
The variables of interest from MSIS were: 
 MRSA test result 
 MRSA test date 
 Diagnosis of colonization or infection 
 Ethnicity 
 Country of birth 
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5.3 Norwegian Patient Registry (A.E.S.A.) 
The Norwegian Patient Registry (NPR) is the national registry of patients who are 
waiting for or have received care at the specialist health care level. The registry was 
created in 1997, but personal ID numbers for each episode of care were not added until 
2008 (Norwegian Directorate of Health, 2015). The data are encrypted, meaning that 
information such as patient name and personal identity number are not stored in this 
registry. The main objectives of the NPR are: 
 To serve as foundation for administration and quality assurance of specialist 
health care services, as well as activity-based financing 
 To contribute to research 
 Serve as a basis for the creation of new disease and quality registries 
 Contribute with information that may prevent accidents and injuries 
 
The variables of interest from NPR were: 
 Age 
 Gender 
 Type of episode of care (inpatient, outpatient, day patient) 
 Primary diagnosis 
 DRG code 
 DRG cost weight 
 Date of admission, date of discharge 
 ID of hospital and ward 
 
In the appendix, Table 4 is a list of the variables from both NPR and MSIS that were 
relevant for our research.  
The data set for our analysis included the patients diagnosed with MRSA and 
their episodes of care at the specialist level. The data also included all of the patients in 
the South-Eastern health region who had received specialist care for the year during the 
period January 1, 2012 to December 31, 2012. The unit of observation was the episode 
of care defined as inpatient, outpatient, or day patient care, with specialist care at a 
hospital. The total number of episodes of care was 3,501,484. The total number of 
individual patients was 984,266.  
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The patients of interest were those diagnosed with MRSA either before they 
received care from the hospital or while they were in hospital. The total number of 
patients in the NPR data set that met this criterion was 315. Patients who were 
diagnosed with MRSA after they had received hospital care (n=234) were excluded. The 
total number of episodes of care for these 315 patients was 961. These episodes 
encompassed inpatient admissions (n=174), outpatient care (n=241), or day patient 
care (n=20). The primary group of analysis among the 315 patients consisted of the 174 
patients who received inpatient care. Variables of interest for this group were their 
length of stay in hospital and the hospital reimbursement amount based on the DRG cost 
weight, as well as the number of inpatient admissions subsequent to their initial 
admission registered in our data.   
 
5.4 Data cleaning (C.J.) 
 Petter Elstrøm of the Norwegian Public Health Institute, in collaboration with the 
authors, did the cleansing of these data to prepare for analyses. After the linkage of the 
MSIS and NPR data sets, five records with missing identification numbers were 
excluded. There were no other inconsistencies, incorrect, or incomplete records that 
needed cleansing. Patients who were registered with MRSA in MSIS but did not receive 
specialist care, thus not registered in NPR, were excluded. Character variables were 
converted into numeric variables. There were inconsistencies in the way individual 
hospitals applied code numbers for each ward. For example, the gynecological wards at 
different hospitals had different ward codes. Recoding was required to identify type of 
wards in each hospital, and to create consistent codes for identical wards for the entire 
health region. 
 
5.5 Statistical analysis (C.J.) 
We carried out a cost analysis of MRSA diagnosed patients. Cost of illness 
analyses involves the identification, measurement and valuing of resources related to an 
illness (European Centre for Disease Prevention and Control, 2009). All statistical 
analyses were performed in Stata Statistical Software (StataCorp, 2013). Simple 
descriptive statistics were presented as proportions and means. Estimation of cost was 
performed by comparing MRSA patients with matched non-MRSA controls. The ratio of 
matched cases to controls aimed to be 1:4. We applied the resampling method of 
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bootstrapping 1000 times to derive 95% confidence intervals (CI) for both cases and 
controls. 
 
5.6 Comparing costs of patients with and without MRSA (both authors) 
We had three measures to evaluate costs: DRG based cost per episode of care, 
length of stay, and the number of episodes of care subsequent to the first episode. The 
DRG codes in the data set were the basis for hospital reimbursement and were used as a 
reference for costs. Within-hospital transfers to different departments/wards were not 
counted as an episode of care unless the date for the transfer was not included in the in-
out period. Matching cases to controls was based on the cases’ first episode of care that 
met the matching criteria (see Table 1).  
To evaluate costs, the cases were matched to controls from the remaining 
patients in the data set who were non-MRSA patients (n= 983,951).  In total, six matched 
control groups were generated. The first matched control group (MC1) was comprised 
of non-MRSA diagnosed inpatients and was used as control group for MRSA diagnosed 
inpatients (n=174). The matching criteria for this group were: inpatient status, age, 
gender, month of hospital admission, primary diagnosis related to the reimbursement 
DRG code, and hospital group. With hospital group we referred to institutions offering 
the same type of services, such as somatic hospitals, rehabilitation, palliative hospitals, 
among others. The dependent variable of interest (the proxy for cost) was the hospital 
reimbursement amount based on the DRG code and weight.  
The second matched control group (MC2) was also comprised of non-MRSA 
diagnosed inpatients, and was also used as a control for MRSA diagnosed inpatients 
(n=174). The main distinction between MC1 and MC2 was that the MC2 criteria included 
matching based on the DRG reimbursement code and did not include primary diagnosis. 
All other matching criteria were the same. The dependent cost variable of interest in this 
matched control was the difference in length of stay.  
As a third level of comparison of treatment costs of patients with and without 
MRSA, we also carried out the matching of cases (n=174) with controls (non-MRSA 
patients) based on age, gender, month of first care-episode, inpatient status, and ward. 
The ward codes in our data set incorporated the health trust, hospital, and the ward to 
which the patient was admitted. With this information, we believed that it would be 
possible to capture similar patients while at the same time avoiding matching on too 
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specific and similar criteria such as the primary diagnosis and DRG. The cost variables of 
interest in this matched control group were: length of stay, hospital reimbursement 
amount based on the principal DRG, and the number of subsequent episodes of care.  
The fourth matched control group (MC4) was used as a control for MRSA 
diagnosed patients (n=315), and included non-MRSA diagnosed patients. The matching 
criteria were: age, gender, ward of treatment, and month of treatment. The dependent 
variable of interest was the number of subsequent episodes of care at all levels of care 
(inpatient, outpatient, or day patient). 
The fifth and sixth matched control groups (MC5 and MC6) were used as controls 
for MRSA diagnosed outpatients (n=241) and MRSA diagnosed day patients (n=20) 
respectively.  These control groups consisted of non-MRSA patients who received 
outpatient care (MC5) and non-MRSA patients who received day treatment at a somatic 
institution (MC6). The matching criteria for MC5 were outpatient status, age, gender, 
ward, and month of treatment, while for MC6 we matched based on day treatment 
status, age, gender, ward, and month of treatment. The dependent variables of interest 
in these matched control groups were the mean number of subsequent episodes and the 
hospital reimbursement amount based on DRGs.  
The matching criteria aimed to create comparable groups that had similar 
characteristics except for the MRSA status. All of the matching criteria were used in an 
attempt to control for confounding. Month of hospital admission or care was a criterion 
for matching since our data were from one year rather than a longer time span. This 
meant that patients with MRSA observed from the time they were diagnosed and in 
contact with specialist care were matched with non-MRSA patients based on the month 
of the MRSA patient’s diagnosis. Thus, a patient diagnosed with MRSA and in contact 
with specialist care in November was matched with a non-MRSA patient who received 
specialist care in November. The variables of interest were then observed for the 
months of November and December. The matching criterion of DRG code was used to 
compare differences in length of stay, as DRG codes place patients in clinically similar 
groups and each DRG code has an average anticipated length of stay incorporated into 
the reimbursement algorithm. Matching on primary diagnosis was also an attempt at 
comparing patients with similar severity of illness. Since MRSA status is not 
incorporated into the DRG classification or primary diagnosis, matching on ward was an 
attempt to control for overmatching based on primary diagnosis and DRG.  
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The ratio of cases to controls aimed to be 1:4. The matched patients were taken 
from the NPR and restricted to patients from the South-Eastern Norway Regional Health 
Authority. The flowchart below shows the groups of analysis.  
 
 
 
Figure 14: Groups of analysis 
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Table 1: Groups of analysis and matching criteria 
Groups Description n 
Group 1 (C1) MRSA diagnosed inpatients 174 
Group 2 (C2) Total MRSA diagnosed patients at all levels of hospital care 315 
Group 3 (C3) MRSA diagnosed outpatients 241 
Group 4 (C4) MRSA diagnosed day patients 20 
Matched Group1 (MC1) Non-MRSA inpatients, match based on primary diagnosis at 
admission 
4 to 1 
Matched Group2 (MC2) Non-MRSA inpatients, match based on DRG reimbursement 4 to 1 
Matched Group3 (MC3) Non-MRSA inpatients, match based on ward 4 to 1 
Matched Group4 (MC4) Non-MRSA patients, at all levels of care match based on 
ward 
4 to 1 
Matched Group5 (MC5) Non-MRSA patients, outpatients match based on ward 4 to 1 
Matched Group6 (MC6) Non-MRSA patients, day patients match based on ward 4 to 1 
MC1 matching 
criteria MC2 matching criteria 
MC3 matching 
criteria 
Age Age Age 
Gender Gender Gender 
Month of admission Month of admission Month of admission 
Primary diagnosis DRG reimbursement Ward 
Hospital Hospital Inpatient status 
Inpatient status Inpatient status   
MC4 matching 
criteria MC5 matching criteria 
MC6 matching 
criteria 
Age Age Age 
Gender Gender Gender 
Month of admission Month of admission Month of admission 
Ward Ward Ward 
  Outpatient status Day patient status 
 
 
5.7 Cost of additional days in hospital (C.J.) 
 The cost of additional length of stay (LOS) was calculated by estimating the mean 
LOS for all the non-MRSA diagnosed inpatients in the data set, then calculating the 
difference in LOS between the MRSA diagnosed inpatients (n=174) and the non-MRSA 
diagnosed mean. The DRG codes have nine aggregate categories for reimbursement: 
basic overhead (administration, etc.), nursing care, intensive care, operations, radiation 
therapy, imaging services, laboratory services, chemotherapy, and implants. Each DRG 
code has a percentage per category by which the total hospital reimbursement is 
divided. In an attempt to not overestimate the additional cost per day by including all of 
the categories, we multiplied the percentage weights per DRG for the categories of 
overhead costs, nursing care costs, imaging services, and laboratory costs. The sum total 
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percentage of these categories was then multiplied by the DRG reimbursement and then 
divided by the mean LOS for non-MRSA inpatients to calculate an average cost per day 
for the four categories per DRG code. This amount was then multiplied by the excess LOS 
for the MRSA patients. 
 
6. Results 
6.1 Patient characteristics - Sample of MRSA positive  (n=315) 
(A.E.S.A.) 
All patients who received specialist health care during year 2012 as registered in 
the NPR were included in this study. The groups of analysis consisted of patients who 
had an MRSA diagnosis prior to or while undergoing hospital care. Patients who 
received their MRSA diagnosis after discharge from the hospital or who were not known 
MRSA positive at the time of hospital care have not been included.  A total of 315 
patients met the inclusion criteria, either as colonized (150 cases) or infected (165 
cases). 
The majority of patients (171) were females, making up 54% of the study 
population while 144 (46%) were males. The mean age for the 315 MRSA positive 
patients was 50 years. Most MRSA patients (60%) were younger than 50 years of age 
(Figure 15 and Table 2) among which 129 (41%) were aged 20 to 49.  With respect to 
place of birth, 55% of the colonized and 69% of the infected were born in Norway, while 
the general Norwegian population consists of 89% born in Norway. All hospitals 
comprised in the South-Eastern Norway Regional Health Authority have rendered 
services to MRSA positive patients during year 2012 (Figure 16), and the hospitals 
serving the largest populations are also the ones with the highest number of MRSA 
cases.  
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Figure 15: Age distribution of MRSA positive patients (n=315) 
 
 
Table 2: Individuals identified with MRSA (n=315), according to age and gender, compared to 
the general Norwegian population of 2012 
Characteristic Infection Colonization Total   
Norwegian 
population 
  n =  165 n =  150 n =  315   n= 4 985 870 
Gender              
Female 86 (52 %) 85 (57 %) 171 (54 %) 2 498 871 (50 %) 
Male 79 (48 %) 65 (43 %) 144 (46 %) 2 486 999 (50 %) 
Age groups                  
0 to 9 12 (7 %) 25 (17 %) 37 (12 %) 611 836 (12 %) 
10 to 19 14 (8 %) 8 (5 %) 22 (7 %) 636 729 (13 %) 
20 to 29 24 (15 %) 21 (14 %) 45 (14 %) 652 787 (13 %) 
30 to 39 19 (12 %) 26 (17 %) 45 (14 %) 677 174 (14 %) 
40 to 49 22 (13 %) 17 (11 %) 39 (12 %) 725 007 (15 %) 
50 to 59 19 (12 %) 13 (9 %) 32 (10 %) 628 176 (13 %) 
60 to 69 20 (12 %) 16 (11 %) 36 (11 %) 535 253 (11 %) 
70 to 79 17 (10 %) 9 (6 %) 26 (8 %) 297 325 (6 %) 
80 to 89 16 (10 %) 11 (7 %) 27 (9 %) 181 642 (4 %) 
90 and above 2 (1 %) 4 (3 %) 6 (2 %) 39 941 (1 %) 
Mean age (Std. Dev.) 53 (26) 48 (24)   50 (25)     
Ethnicity               
Born in Norway 114 (69 %) 83 (55 %)   197 (63 %) 4 439 138 (89 %) 
Born abroad 51 (31 %) 67 (45 %)   118 (37 %) 546 732 (11 %) 
 
(MSIS and Statistics Norway, 2012) 
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Figure 16: The MRSA patients (n=315) according to hospital 
 
 
6.2 Patient characteristics - Sample of inpatients (n=174) (A.E.S.A.) 
A subsample of 174 patients, consisting only of patients who received care 
services in the hospital (inpatient care) and who were known MRSA positive according 
to the criteria stated before, made up our primary group of analysis. Among the 174 
inpatients, 87 cases were colonization and 87 were infection. In total, 88 (51%) were 
males. 
Age distribution showed that the number of patients aged 10-19, 70-79, and 90 
and above was lower than in other age groups. Patients less than 50 years of age made 
up 51% (88 patients) of the total. The most notable differences in age observed between 
the colonized and the infected patients, was in age group 0-9 year olds, constituting 14% 
of the colonized and only 9% of infected; as well as 30-39 year olds, comprising 15% of 
the colonized patients and only 7% of infected.  The mean age of the 174 inpatients was 
47 years of age.  
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 Figure 17: Age distribution of inpatients (n=174) 
 
 
The two hospitals in the South-Eastern Health Region that had the most cases of 
MRSA positive patients were Oslo University Hospital which serves more than half a 
million inhabitants, with 52 MRSA diagnoses constituting 30% of our sample, and 
Akershus University Hospital, with 33 MRSA diagnoses constituting 19% of our sample 
(Figure 18).  Oslo University Hospital is a highly specialized hospital offering services to 
the citizens of Oslo, as well as handling extensive regional and national tasks (Oslo 
University Hospital, 2015). It had approximately 1500beds for somatic services in 2012. 
Akershus University Hospital moved into new facilities in October 2008. It is a somatic 
hospital and serves approximately half a million inhabitants in Follo, Romerike, 
Roemskog and the three northernmost districts in Oslo (Alna, Grorud and Stovner) 
(Akershus University Hospital, 2015). This hospital had approximately 700 beds for 
somatic services in 2012.  
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Figure 18: Inpatients (n=174) according to hospital 
 
6.3 Cost analysis based on matched groups 
6.3.1 DRG based reimbursement (C.J.) 
The mean cost of the 174 inpatients was NOK71,206 (95% CI NOK47,456-
94,956) according to the DRG weights while it was NOK56,653 (95% CI NOK48,278-
65,028) among the controls when controlling for primary diagnosis (MC1). When 
controlling for hospital and ward (MC3), the mean cost of the 174 inpatients was 
NOK74,644 (95% CI NOK50,820-98,468) according to the DRG weights, while it was 
NOK49,511 (95% CI NOK44,363-54,659) among the controls.   There were minimal 
differences (less than NOK750) in reimbursement when comparing MRSA outpatients 
(C3) and day patients (C4) with their respective controls (MC5 and MC6). In both 
analyses, the bootstrapped 95% CI were slightly wider in the cases compared with their 
respective controls, but there was no significant difference in either group. 
 
6.3.2 Length of stay (C.J.) 
The two analyses of LOS for inpatients both revealed that MRSA inpatients 
(n=174) stay in the hospital approximately 3 days longer, on average, compared with 
their respective controls (MC2 and MC3). The bootstrapped 95% CI showed no overlap 
between cases and controls, in either analysis, indicating a significant difference 
between the groups. The span of the 95% CI in the controls did not exceed 1.5 days; 
where as, the span of the 95% CI in the cases was approximately 3 days. 
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6.3.3 Subsequent episodes of care (C.J) 
The MRSA positive inpatients (n=174) had almost twice as many subsequent 
episodes compared to their matched controls (MC3). There was a significant difference 
in this analysis revealed by the bootstrapped 95% CI (Table 3). The other analyses 
showed that the number of subsequent episodes of care for all MRSA patients (n=315) 
was slightly less than the controls (MC4). When the patients were analyzed according to 
the level of care, outpatient (n=241) and day patient (n=20), the MRSA cases continued 
to have a slightly lower number of subsequent episodes of care compared with their 
respective controls. Only the MRSA inpatients (n=174) had a significant difference in the 
number of subsequent episodes.  
 
6.3.4 Cost of excess LOS (A.E.S.A.) 
The cost of additional LOS for the MRSA inpatients (n=174) was based on the 
average DRG fraction including overhead costs, care costs, imaging services, and 
laboratory costs per additional day.  This represented 87% of the total DRG cost weights, 
which translated to an average of NOK7,863 per additional day in hospital. MRSA 
inpatients had a mean excess LOS of three days compared with their matched controls. 
Hence, the average total additional cost of excess LOS for MRSA inpatients is estimated 
to be NOK23,589 per case.  
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Table 3: Comparison of costs, LOS, and subsequent episodes of care between MRSA patients and 
matched controls 
Analysis 
Groups of 
comparison 
n Results (bootstrapped 95% CI) 
Mean cost per episode of care 
based on DRG cost weights 
C1 vs MC1 144 vs 527 NOK71,206 (47,456 -94,956)  NOK56,653 (48,278-65,028) 
Mean length of stay (days) C1 vs MC2 162 vs 606 8.5 (6.9 - 10.1)   5.4 (4.9 - 6.1) 
Mean cost per episode of care 
based on DRG cost weights 
C1 vs MC3  170 vs 671 NOK74,644 (50,820-98,468)  NOK49,511 (44,363-54,659) 
Mean length of stay (days) C1 vs MC3 170 vs 671 8.2 (6.6 - 9.9)  4.6 (4.1 - 5.2) 
Mean number of episodes of care 
subsequent to the initial matched 
episode 
C1 vs MC3 170 vs 671 1.5 (1.1 - 1.9)   0.8 (0.68 - 0.89) 
Mean number of episodes of 
hospital care at all levels 
C2 vs MC4 313 vs 1247 4.1 (3.41 - 4.78)   4.2 (3.70 - 4.80) 
Mean cost based on DRG cost 
weights 
C3 vs MC5 239 vs 953 NOK1,318 (1,106 - 1,530)   NOK1,438 (1,344 - 1,532) 
Mean number of subsequent 
episodes 
C3 vs MC5 239 vs 953 2.90 (2.39 - 3.42)   3.25 (2.82 - 3.68) 
Mean cost based on DRG cost 
weights 
C4 vs MC6 19 vs 72 NOK8,435 (5,854 - 11,015)  NOK9,182 (7,640 - 10,724) 
Mean number of subsequent 
episodes 
C4 vs MC6 19 vs 72 2.42 (-1.58 - 6.42)  4.19 (-0.13 - 8.52) 
 
 
7. DISCUSSION 
7.1 Main summary(C.J.) 
Antibiotic resistant pathogens, such as MRSA, pose a serious risk to public health. 
In order to control the spread and prevent an endemic presence of MRSA within its 
health care facilities, Norway developed comprehensive guidelines for screening and 
isolating patients carrying this pathogen. Currently, the activity-based financing of 
somatic institutions does not incorporate the additional economic burden born by 
hospitals to apply these guidelines. To evaluate the costs associated with patients 
diagnosed with MRSA who received specialized care in the South-Eastern Norway 
Regional Health Authority during the year 2012, we estimated and compared the LOS, 
the number of subsequent episodes of care, and the DRG cost weight reimbursement for 
MRSA patients and a series of matched control groups. Awareness of these expenditures 
is critical for cost-effectiveness analysis to evaluate the impact of intervention methods 
and infection control programs, as well as to make informed policy decisions. 
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7.2 Strengths of the study (C.J.) 
 Strengths of this study were the reliability of our proxies for cost, as well as the 
quality, accuracy, and completeness of the data set utilized for analyses. The data set 
included the actual LOS per episode of specialized care for all patients in the health 
region.   
These results are generalizable to Norway and Norwegian hospitals as the South 
Eastern Norway Regional Health Authority represents the 56% of the population, and 
the DRG reimbursement system is a part of the national government’s hospital financing 
scheme. 
 The detailed recoding of hospitals and hospital wards to identify types of wards 
in each hospital to create consistent codes for identical wards across the entire health 
region facilitated reliable matching based on ward. This type of comparison allowed for 
matching patients that were similar with respect to type of acute care, but not too 
similar that differences were not captured when matching on DRG code or primary 
diagnosis.  
 
7.3 Limitations of the study (C.J.) 
A general limitation that must be considered is the nature of retrospective 
register-based studies. Using observational data that were collected retrospectively 
commonly leads to the exclusion of relevant risk factors. In turn, the observational 
nature of the study means that only association, not causation, can be inferred. In our 
case, we can only assume there is a correlation with having MRSA and lengthened 
hospital stay, and thus increased costs, since this association could be the result of 
confounding. To expand, there may be other risk factors characteristic of our patient 
sample that contribute to their LOS, other than their MRSA status. Patients with MRSA 
tend to be older and sicker than the general population. Although we have attempted to 
control for this by matching on various criteria, we can only infer correlation. 
The use of an average gross-costing measure, such as the DRG, bears with it 
certain limitations, and capital costs were not included. With respect to decision-making, 
marginal costs should be measured, including a detailed micro-costing approach.  The 
time restriction and availability of these data limited us to the use of average cost 
reimbursement based on the DRG cost weight.  Also, the use of the DRG reimbursement 
to hospitals has recently been criticized by the Office of the Auditor General of Norway 
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due to inconsistencies in the DRG coding practices, leading to erroneous DRG code in 1 
out of 4 hospital admissions (Office of the Auditor General of Norway, 2009). On the 
other hand, the actual measures required to be taken when treating MRSA patients, such 
as isolation, material costs (caps, gowns, gloves, etc.), disinfection costs, antibiotic use, 
among others, are not incorporated into the DRG code reimbursement, and thus, the 
DRG reimbursement could be an underestimate of the actual resource burden to the 
hospital.   
According to Cosgrove and Carmeli (2003), it is important to understand the 
perspective of a study when interpreting its results, as studies that evaluate one 
perspective can undervalue the impact of antimicrobial resistance. A hospital 
perspective is a limited view of the overall effect of microbial resistance on the health 
care system, as much of clinical care is now provided in long-term care facilities and 
rehabilitation centers (Cosgrove and Carmeli, 2003). This study was conducted from a 
hospital’s perspective and focused therefore on MRSA attributable costs to the hospital. 
A societal perspective which considers production loss due to morbidity and death, costs 
to the individual (transportation, lost leisure time, lost wages), diminished quality of life, 
among others, would have resulted in a more comprehensive cost estimate of the 
economic burden that MRSA poses to society as a whole. The cost of antibiotic use to 
society should also be included, as the rate at which organisms are developing 
antimicrobial resistance is quickly eliminating the effectiveness of certain valuable 
antibiotics. Additionally, a significant cost to consider is the impact of isolation on the 
patient. According to Gould (2006), there is an association between isolated patients and 
poorer standards of care, as well as patients suffering from anxiety and ostracization 
due to isolation.  
We were limited to data from one year (January 1-December 31, 2012), which is 
a major limitation for several reasons. Patients with a MRSA diagnosis are generally 
sicker and older than the average patient, and using LOS as a proxy for resource use may 
artificially inflate the impact of the presence of MRSA. We were unable to control for 
pre-MRSA status severity of illness and LOS. A longer time period of observation 
including pre-MRSA severity of illness would have allowed for adjustments to be made. 
Additionally, a one-year period does not allow for observing the long-term effects of 
MRSA status for the individual patients, which are known to have extended morbidity 
after discharge (Gould, 2006). A short-term analysis also leads to lack of information 
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about the cost of mortality, which was not observed in this analysis. The valuation of 
mortality is difficult, but should be considered a variable of interest in a long-term 
evaluation of cost.   
 
7.4 Discussion of findings (both authors) 
The results of this study reveal that MRSA diagnosed inpatients have an average 
LOS in the hospital that was three days longer than their respective matched controls 
(8.5 vs. 5.4 and 8.2 vs. 4.6). These findings support our hypothesis regarding this patient 
population’s LOS in the hospital. The underlying reasons for this difference can vary and 
no conclusions as to the cause can be drawn. The patients in this group may have had 
the same average LOS without the presence of MRSA. 
Something to be considered when reflecting on these findings is the Norwegian 
protocol of preemptive isolation of patients who are suspected of having MRSA. 
According to our sources from Akershus University Hospital, the average time in 
preemptive isolation of patients suspected of MRSA is three days. In theory, according to 
the national guidelines, these patients are to be treated with the same priority as all 
other patients, but in practice there is a possibility that patients with an “unknown” 
MRSA status may have delays in receiving other diagnostic exams because of the 
additional precautions that must be taken. For example, an unknown MRSA patient in 
preemptive isolation may be placed on hold for imaging services until the MRSA status is 
conclusive. The waiting time for screening results may contribute to delayed care for 
these patients, which in turn could prolong the LOS. If delays in care for patients in 
preemptive isolation is what occurs in practice, policy makers must explore ways to 
incentivize hospitals in order to assure timely care for these patients.  
The prevention and control measures for MRSA are rigorous in Norwegian 
hospitals, adding to the time health personnel spend on each patient who is isolated. 
Care is provided according to the patient’s needs so each case is unique. Nevertheless, 
there are certain routines and practices that make it necessary for staff to have contact 
with the isolated patient (serving of meals three times a day, blood tests, changing of bed 
linens every day, among other). After each contact with an isolated MRSA patient, staff 
must make sure that all equipment is disinfected and waste is properly disposed before 
it can be moved out of the isolation room. Contaminated waste means higher costs to the 
hospital, as this kind of waste must be handled with particular care. This indicates that 
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our estimates of costs related to MRSA in hospitals, based on LOS and DRG 
reimbursement, may have greatly underestimated the real costs of this condition.  
In 2010, Jinshuo Li conducted a detailed cost-effectiveness analysis of screening 
methods for MRSA patients at Ullevål Hospital, which falls under the Oslo University 
Hospital Trust. In this analysis, Li presented details on the micro-costs of screening and 
preemptive isolation of suspected MRSA patients. This included testing costs, labor 
costs, material costs, and the cost of disinfecting the room where patients were isolated. 
The total cost of these resources based on the use of a bacteriological culture test for 
screening was NOK17,753 (NOK based on the year 2012), per episode of screening and 
preemptive isolation. As many Norwegians travel abroad and come in contact with 
foreign health care facilities, fulfilling the criteria for MRSA screening, we believe it 
would be advisable for the health authorities to further investigate the number 
of  patients who are screened for MRSA with negative test results. A cost-effectiveness 
evaluation of the preemptive isolation and screening should be considered, as these 
resources may be more effectively used for other purposes.  
The MRSA diagnosed inpatients (n=174) had a mean reimbursement NOK25,133 
higher than their respective controls when matched according to hospital and ward 
(MC3) (NOK74,644 vs. 49,511) supporting our hypothesis that this patient population 
had on average a higher DRG cost weight reimbursement. As discussed previously, the 
DRG cost weight as a proxy for cost has its limitations, but what is clear from these 
findings is that MRSA inpatients have a higher mean reimbursement when compared 
with similar patients in the same hospital ward. As the MRSA status is not incorporated 
into this reimbursement, and neither are the actual costs of infection control measures 
and isolation, this difference is most likely a severe underestimate of the actual 
resources used by the hospital to care for these patients.  
 There was also a significant difference in the mean number of subsequent 
episodes of care when comparing inpatients (n=174) with controls matched according 
to ward (MC3) (1.5 vs. 0.8 episodes). The mean numbers of subsequent episodes of care 
were not significantly different between MRSA cases and controls when comparing all 
MRSA patients (n=315), outpatients (n=241), and day patients (n=20) with their 
respective controls (Table 3). In fact, with each comparison, MRSA patients had slightly 
lower average numbers of subsequent episodes. This was not expected as we 
hypothesized more subsequent episodes of care for MRSA patients. Again, considering 
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the additional resources used by hospitals to care for these patients, policy makers 
should enact their role as complementary agent and create incentives for timely and 
appropriate care. Otherwise, there could be a possibility that hospitals may try to avoid 
this patient population because of the extensive resources used for infection control and 
isolation. 
 
7.5 Findings in other studies (A.E.S.A.) 
Our results of costs per identified MRSA case in Norwegian hospitals (NOK71,206 
when controlling for primary diagnosis and NOK74,644 when controlling for hospital 
and ward) are in accordance with previous studies such as the German study by Hübner 
et al. (2014) in which the cost per identified MRSA case was estimated to €8,673, which 
with an average exchange rate of NOK7,48 for 2012, is equivalent to NOK64,874. One 
important distinction from the German study is that we have used a gross-costing 
measure, the DRG, to estimate the costs related to MRSA, while the German authors have 
accounted for costs related to hygienic measures, laboratory and opportunity costs of 
blocked beds. Opportunity cost of blocked beds accounted for 77% of the total cost per 
case of MRSA in the German study. This is likely a significant cost for Norwegian 
hospitals also as there are issues with having enough capacity for inpatient stays. 
Although, being that individual Norwegian hospitals are structured differently and have 
capacity issues of varying degrees, estimating the opportunity cost of bed blocking is 
difficult, but should be considered in future studies. Excess LOS as estimated by Hübner 
et al. was 2.6 days for MRSA patients when compared to other patients in the same G-
DRG classification, which is very close to our findings of average excess LOS of 3 days for 
MRSA patients when compared to their control groups. 
Another study, performed by Swiss authors Macedo-Viñas et al. in 2013 at the 
University of Geneva Hospitals, estimated that additional MRSA related costs averaged 
CHF800 per day, which with an average exchange rate of NOK6.21 for 2012, is 
equivalent to NOK4,968 per day. Given our findings on mean excess LOS of at least 3 
days for MRSA patients, and additional costs of NOK23,589 compared with their control 
groups, we have an average daily cost of NOK7,863. The Swiss authors’ findings on mean 
excess LOS (15.3 days according matched analysis) was very different from ours (3 
days). This may be explained by the fact that the Swiss study only included patients who 
required systemic antibiotics and had severe infections, while we included all inpatients 
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with a known MRSA diagnosis, regardless of severity of illness. For these reasons, the 
excess LOS as found in the Swiss study could possibly be explained primarily by the 
severity of the infections, whereas there are very few serious MRSA infections in 
Norway, less than 25 cases per year from year 2000 to 2010, according to the 
Norwegian Institute of Public Health. 
An American study by Bruce Y. Lee et al. (2013) estimated the economic burden 
of CA-MRSA to third-party payers to $2,277 - $3,200 (equivalent to NOK13,252 - 18,624 
with 2012 exchange rate of NOK5.82), including only direct medical costs such as 
outpatient/Emergency Room visit, hospitalization and treatment. Their estimated costs 
to society were 3-5 times higher than the third-party costs. This could possibly imply 
that our cost estimates based on LOS from a hospital perspective are grossly 
underestimating the costs MRSA poses to society, as we are not taking into 
consideration the cost burden imposed to society through lost productivity, lost income, 
lost quality of life and life years, among others. 
 
7.6 Policy implications (both authors) 
Given that the prevalence of MRSA is very low in Norway, the “search and 
destroy” approach seems to have positive effects and should, if possible, be carried on. 
According to van Rijen and Kluytmans (2009), and their analysis of a Dutch hospital, 
applying the “search and destroy” approach in countries with low endemic MRSA 
incidence saves lives and costs. The “search and destroy” method includes early 
detection, early identification and efforts to contain spread. Various strategies are used 
in this method, such as, isolation of patients, work restrictions for staff members that are 
colonized, screening of staff and patients, and use of decolonization methods (Hughes et 
al., 2013).  
The implementation and adherence to the national guidelines (MRSA-Veilederen) 
for preventing and containing the spread of MRSA in Norwegian health care facilities 
should be continuously followed up in the most populated health regions. However, the 
most costly and transcendent control measure, contact isolation in single room, has been 
associated with reduced contact between health care workers and the patient by 40%-
50%, reduced quality of patient care and adverse psychological impact on the patient 
(Wassenberg, 2010). These guidelines should, therefore, be under constant supervision 
from policymakers, and continuously revised according to the ever-changing health 
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threat situation, in consensus with professionals in the area.  It should be a goal to 
reduce the number of days patients spend in isolation if their MRSA diagnosis result is 
negative.  
With increased patient mobility in Europe and particularly, within the EU, there 
is also a risk of patients who receive care abroad, getting infected with bacteria and 
viruses which the Norwegian health care system has managed to keep under control. 
Hence, it is important that screening practices continue, are refined, and that policy 
makers prioritize sustained development of screening methods.  
The economic burden of MRSA in hospitals is high, primarily due to the increased 
LOS and the extensive hygienic measures that must be taken to contain the spread of 
MRSA (Hübner et al., 2014). As of today, hospitals in Norway do not have a practice of 
accounting for the additional cost burden of MRSA and are not being fully reimbursed 
for these costs. Therefore, there is a need for more information about the detailed costs 
associated with MRSA. Quantifying the additional LOS for MRSA inpatients is important 
for the fiscal stability of hospitals and the overall health care budget.  
The importance of incentivizing infection controls measure in hospitals cannot be 
overstated, especially when considering the unseen cost savings of preventing the 
spread of antimicrobial resistance. As discussed in chapter 3.3, it is the policy maker’s 
role to act as a complimentary agent so that they can bring balance to the principal-
agent relationship. For policy makers to act in the best interest of MRSA patients, as well 
as the overall population, they must be adequately informed of the resources used and 
economic burden of this group. A lack of information about the costs of MRSA raises 
concerns with regards to the spread of the infection within hospital settings and health 
care facilities, as well as, increased antibiotic resistance in the population due to overuse 
and non-adherence to treatment. We advise that policy makers consider a national 
methodology for somatic institutions to systematically account for the detailed costs of 
the extensive hygienic measures, the cost of isolation, and the additional labor costs 
associated with caring for MRSA patients. With an accurate account of the economic 
burden of MRSA in hospitals, correct remuneration could be assured to incentivize 
quality care for this patient population, and in turn, contain the spread of antimicrobial 
resistance in Norway.  
 53 
8. Conclusion (both authors) 
To our best knowledge, this is the first study to estimate the cost burden of MRSA 
in hospitals in the South-Eastern Norway Regional Health Authority. A statistically 
significant difference in LOS was seen between MRSA inpatients (n=174) and respective 
matched controls (MC2 and MC3). MRSA patients were also more costly than respective 
controls, based on their DRG reimbursement. In addition, there was a significant 
difference in the number of subsequent episodes of care for MRSA inpatients (n=174) 
compared with matched controls (MC3). These measures of resource use are most likely 
an underestimate of the economic burden of this patient population.  
This study may be used as starting point for future economic evaluations to 
further assess the extent of the economic and societal impact of MRSA. It is essential that 
additional study in this area be done to estimate the micro-costs of infection control 
measures, the cost of isolation, and the marginal costs of caring for this patient 
population. Additional research should consist of various perspectives, including but not 
limited to, the hospital perspective. The health authorities should consider and further 
explore the potential imbalance in the hospital reimbursement for this patient 
population so that hospitals may be appropriately incentivized to provide proper and 
timely care. The extensive infection control measures applied in Norwegian health care 
facilities are resource intensive.Further study and economic evaluations are imperative 
so that policy makers may be sufficiently informed when priority setting and decision-
making is involved.  
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Appendices 
Appendix A 
List of relevant variables 
 
 
Table 4: Relevant variables from MSIS and NPR 
Variable Name Explanation 
Main Groups 
MRSA status 
1: MRSA-positive 
0: MRSA-negative 
Positive  1: MRSA-positive & registered in NPR 
Negative  1: MRSA-negative & registered in NPR 
Database 
1: NPR-data 
0: MSIS-data 
Episode 
Episode = Episode-serial number. Each patient has received a 
serial number for each new episode in the hospital (the first 
treatment in the hospital is designated xhlnr=1) 
Each patient that is only registered in MSIS also has the 
designation xhlnr=1 
Descriptive variables from both MSIS and NPR 
Sex 
1: Male 
0: Female 
Municipality Municipality of residence 
District District patient resides in 
Descriptive variables only from MSIS data 
Ethnicity  
Ethnicity based on mother and father’s place of birth (ancestry) 
1: Norwegian (born in Norway, Norwegian born parents) 
2: second generation immigrants (born in Norway, foreign born 
parents or adopted from abroad) 
3: first generation immigrants (born abroad, reside in Norway) 
4: Temporary stay (born and live abroad) 
9: unknown (not registered) 
Norwegian birth 
1: born in Norway 
0: born abroad 
County  County that patient lives in and is registered 
Diagnosis 
1: MRSA-infection 
0: MRSA-carriage 
MRSA type Genotype (spa-type) for bacterial isolates 
PVL 
PVL = Panton Valentin Leukocidin: a gene associated with 
increased virulence 
1: PVL-positive 
2: PVL-negative 
VRE 
VRE = infection/ carrier of Vancomycin-resistant Enterococci 
1: VRE-positive 
0: VRE-negative 
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Descriptive variables only from NPR data 
Age Age: numeric integers, range 0 – 113 
Age group Age group: numeric, 10-year intervals 
Episodes total  Total episodes per patient 
Description of episodes only in NPR data 
Outpatient 
1: outpatient consultation 
0: other episode in hospital (day or inpatient treatment) 
Day treatment 
1: day treatment 
0: other episode in hospital (outpatient clinic consultation or 
day treatment) 
Admitted  
1: admitted as inpatient 
0: other episode in hospital (outpatient consult or day 
treatment) 
Screening date Date for MRSA screening test 
In date 
Date for hospital treatment (outpatient clinic, day treatment, 
inpatient admission) 
Out date Date of release 
Days 
Total days of treatment (in date minus out date) 
Outpatient clinic and day treatment are assigned 1 instead of 0 
Screening days 
Number of days from MRSA test to hospital treatment (+ n: 
positive MRSA test was taken before or the day of treatment, -n: 
positive MRSA sample was taken after treatment) 
Known MRSA 
1: MRSA diagnosis assigned before or the day of treatment 
0: MRSA diagnosis was assigned after the start of treatment 
Hospital diagnosis 
1: MRSA diagnosed started treatment in hospital 
0: MRSA was diagnosed in healthcare facility other than hospital 
Health code Numeric code for health: 11 – 25 
Hospital code Numeric code for hospital - physical location, 11 - 55 
Department 
Code (string) for each department, based on variable 
department names (code numbers.) ward type and hospital 
Department code Numeric code for department 
Corrected department codes 
Numeric code for department after correcting coding errors 
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Appendix B 
Groups of analysis 
 
Figure 19: Flow chart of inpatient analysis (n=174) 
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Figure 20: Flow chart of analysis of all MRSA patients (n=315) 
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Figure 21: Flow chart of outpatient analysis (n=241) 
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Figure 22: Flow chart of day patient analysis (n=20) 
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Appendix C 
Primary diagnoses of MRSA patients 
 
Table 5: The most common illnesses among MRSA positive patients (n=315) 
Primary 
diagnosis code 
Description 
Frequency (%) of 
total 
L02 Cutaneous abscess, furuncle and carbuncle 28 8,86 % 
Z03 
Encounter for medical observation for suspected 
diseases and conditions ruled out 7 2,22 % 
Z01 Routine examination of specific system 6 1,90 % 
Z09 
Encounter for follow-up examination after completed 
treatment for conditions other than malignant 
neoplasm 6 1,90 % 
Z36 Encounter for antenatal screening of mother 6 1,90 % 
K61 Abscess of anal and rectal regions 5 1,58 % 
A41 Sepsis due to Staphylococcus aureus or MRSA 5 1,58 % 
A46 
Erysipelas: An acute infection of the skin caused by 
species of streptococcus. 5 1,58 % 
J44 Other chronic obstructive pulmonary disease 4 1,27 % 
L08 Other local infections of skin and subcutaneous tissue 4 1,27 % 
N61 Inflammatory disorders of breast 4 1,27 % 
S01 Open wound of head 4 1,27 % 
S06 
Intracranial injury. Brain injury resulting from an 
accident, surgery, or other trauma. 4 1,27 % 
Z22 Carrier of infectious disease 4 1,27 % 
Z37 Outcome of delivery 4 1,27 % 
(icd10data.com, 2015) 
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Table 6: The most common illnesses among inpatients (n=174) 
Primary 
diagnosis code 
Description 
Frequency (%) of 
total 
Z37 Outcome of delivery 15 8,62 % 
L02 Cutaneous abscess, furuncle and carbuncle 13 7,47 % 
A41 Sepsis due to Staphylococcus aureus or MRSA 6 3,45 % 
A46 
Erysipelas: An acute infection of the skin caused by 
species of streptococcus. 4 2,30 % 
K61 Abscess of anal and rectal regions 4 2,30 % 
S06 
Intracranial injury. Brain injury resulting from an 
accident, surgery, or other trauma. 4 2,30 % 
T81 Complications of procedures 4 2,30 % 
I63 
Cerebral infarction: An ischemic condition of the brain, 
producing a persistent focal neurological deficit in the 
area of distribution of the cerebral arteries. 3 1,72 % 
J15 
Bacterial pneumonia. Bronchopneumonia due to 
bacteria other than S. pneumoniae and H. influenzae 3 1,72 % 
J44 Other chronic obstructive pulmonary disease 3 1,72 % 
J45 
Asthma: A chronic respiratory disease manifested as 
difficulty breathing due to the narrowing of bronchial 
passageways. 3 1,72 % 
L08 Other local infections of skin and subcutaneous tissue 3 1,72 % 
N17 Acute kidney failure 3 1,72 % 
Q37 
Cleft palate with cleft lip. Cleft lip and cleft palate are 
birth defects that affect the upper lip and roof of the 
mouth 3 1,72 % 
R07 Pain in throat and chest 3 1,72 % 
(icd10data.com, 2015) 
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Appendix D 
Structural organization of the South-Eastern Norway Regional Health Authority 
 
 
Figure 23: Structural organization of the South-Eastern Norway Regional Health Authority 
(Helse Sør-Øst, 2012) 
 
 
Appendix E 
MRSA cases in Norway from 2006-2013 
Table 7.Infection and colonization with Methicillin-resistant S. aureus (MRSA) in Norway 2006-
2013 according to year of diagnosis and place of contraction 
 
Year 2006  2007  2008  2009  2010  2011  2012  2013 
Health care facility 
in Norway 
253 216 202 205 232 228 236 291 
Community  218 218 230 318 332 406 457 558 
Abroad 159 170 226 296 345 425 515 633 
Total 630 604 658 819 909 1059 1208 1482 
 
(Norwegian Institute of Public Health, 2015) 
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Appendix F 
Methicillin-resistant Staphylococcus aureus in Europe from 2012 
 
 
Figure 24: Proportion of Methicillin Resistant Staphylococcus aureus (MRSA) Isolates in 
Participating Countries in 2012 
(ECDC, 2012) 
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Appendix G 
Contact isolation protocol and screening criteria 
 
Table 7: Description of protocol for contact isolation 
 
(Ahus, 2015) 
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Figure 25: Screening criteria for MRSA test 
 (Ahus, 2015) 
